Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PRIVATE LABEL MANUFACTURERS SHOULD CAPITALIZE ON BRAND NAME LAUNCHES

This article was originally published in The Tan Sheet

Executive Summary

PRIVATE LABEL MANUFACTURERS SHOULD CAPITALIZE ON BRAND NAME LAUNCHES by being on the shelf within 18 months of the brand name's introduction, Duane Reed Senior VP-Sales and Marketing Gary Charboneau told the Private Label Manufacturers Association's annual meeting in Miami on March 27. "What better time to be on the shelf with a store brand than during this launch period," he pointed out. Charboneau, who recently left CVS after twelve years to join Duane Reed, suggested that private label manufacturers "take advantage of the national brand advertising of product attributes and generate store brand trial before a consumer forms strong preferences for taste, texture, fragrance or color." A new national brand item "experiences its greatest period of trial in its first 18 months on the shelf," he explained. "Consumer marketing and advertising programs are at their peak during the launch period and additional trade dollars flow heavily to generate distribution and initial retail promotional support." In his presentation entitled "New Directions for Drug Chains," Charboneau explained how manufacturers can add value to their private label lines for their retailer customers. He pointed out that "it's becoming important enough [for retail chains] to make being six weeks or eight weeks ahead of [other private label manufacturers] in bringing a product to the shelf the key reason to select you as the supplier of that item. A few pennies of difference in the price would be less important to me than being first on the shelf with a new item." The drug chain exec noted that "as retailers learn the competitive advantage that speed represents, [private label] manufacturers who have focused on using speed as an added value will . . . gain a leg up on others when it comes to the decision of who to award a new item to." With new items, he declared: "Be first. Be best." Charboneau also emphasized package design to the private label audience. He suggested that private label "packaging should be designed so there's no question in the customer's mind whose product they're purchasing." A store brand's line should look like a "family" of products that tells "a consumer that these products are cut from the same cloth of savings and product performance." Consistent positioning and sizing of the logo says that "these products are related and share the attributes important to the consumer," he said. Private label manufacturers should also take part in helping retailers "decide on attributes they want to communicate" in their packaging, Charboneau observed, and limiting the number to three. "More than that gets tricky," he said. Charboneau suggested that private label manufacturers also participate in "advertising and in-store communications that focus on these attributes." Charboneau recommended that "adding value to your selling proposition will help you move further ahead of those selling on price alone." He added: "I know that this is a healthy year for private label manufacturers and the time to do it is when you're healthy, not when you're struggling."

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS081304

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel